Literature DB >> 34579969

Gut microbiome-oriented therapy for metabolic diseases: challenges and opportunities towards clinical translation.

Xueli Zhang1, Xiaoying Cai2, Xiao Zheng3.   

Abstract

Gut microbial changes have been causally associated with metabolic diseases, triggering huge interest in designing gut microbiome-based therapy. Here we discuss the open questions and challenges of translating ongoing gut microbiome-based intervention strategies to safe and efficacious clinical therapies. We also consider how the accumulating insights into host-microbe interactions in metabolic regulation could be harnessed as new dimensions to strengthen the translational prospect.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  clinical translation; drug discovery; gut microbiome; host–microbe interaction; metabolic diseases

Mesh:

Year:  2021        PMID: 34579969     DOI: 10.1016/j.tips.2021.09.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  2 in total

1.  Functional Characterization of Clostridium tyrobutyricum L319: A Promising Next-Generation Probiotic for Short-Chain Fatty Acid Production.

Authors:  Zhihan Yang; Fatima Ezzahra Amal; Lei Yang; Yuxin Liu; Liying Zhu; Zhengming Zhu; Ling Jiang
Journal:  Front Microbiol       Date:  2022-06-17       Impact factor: 6.064

Review 2.  The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs.

Authors:  Marie S A Palmnäs-Bédard; Giuseppina Costabile; Claudia Vetrani; Sebastian Åberg; Yommine Hjalmarsson; Johan Dicksved; Gabriele Riccardi; Rikard Landberg
Journal:  Am J Clin Nutr       Date:  2022-10-06       Impact factor: 8.472

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.